CHSU Discovery

Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials.

International journal of cancer Peer reviewed publication
volume 150 issue 5 pages 727-740
3/1/2021
DOI: 10.1002/ijc.33811 PMID: 34536299
EISSN: 1097-0215 ISSN: 0020-7136 LN: Neiheisel LN: Shenoy LN: Kaur LN: Ma CHSU: Faculty CHSU: Student LN: Shenoy A LN: Shenoy Anitha

Repository

Description

Wnt signaling plays an essential role in the initiation and progression of various types of cancer. Besides, the Wnt pathway components have been established as reliable biomarkers and potential targets for cancer therapy. Wnt signaling is categorized into canonical and noncanonical pathways. The canonical pathway is involved in cell survival, proliferation, differentiation and migration, while the noncanonical pathway regulates cell polarity and migration. Apart from its biological role in development and homeostasis, the Wnt pathway has been implicated in several pathological disorders, including cancer. As a result, inhibiting this pathway has been a focus of cancer research with multiple targetable candidates in development. In this review, our focus will be to summarize information about ongoing and completed clinical trials targeting various Wnt pathway components, along with describing current and emerging Wnt targeted therapies. In addition, we will discuss potential opportunities and associated challenges of inhibiting Wnt signaling for cancer therapy.

Show Full Abstract Collapse Abstract

Affiliations

  1. College of Pharmacy, California Health Sciences University, Clovis, California, USA.
  2. Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, California Health Sciences University, Clovis, California, USA.
  3. Kaweah Health Foundation, Kaweah Health, Visalia, California, USA.

Location

United States

Languages

English
Loading...